<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394598</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-R20</org_study_id>
    <nct_id>NCT04394598</nct_id>
  </id_info>
  <brief_title>A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer</brief_title>
  <official_title>A Phase II Randomized Study of the Protection Effect of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the addition of Chinese Herbal Compound Dendrobium Huoshanense Granules
      to capecitabine and irinotecan in neoadjuvant chemoradiation(CRT) in locally advanced rectal
      cancer. Half of participants will receive CRT with Dendrobium Huoshanense Granules, while the
      others will receive CRT with placebo. We will evaluate whether Dendrobium Huoshanense
      Granules can enhance the immune function and alleviate symptoms caused by the tumor and CRT .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the morbidity of hematological adverse events and diarrhea as assessed by CTCAE v4.0</measure>
    <time_frame>twice weekly during the neoadjuvant chemotherapy (5 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of participants' quality of life during treatment as assessed by EQ-5D questionnaire</measure>
    <time_frame>once weekly during the neoadjuvant chemotherapy (5 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of participants' quality of life during treatment as assessed by EORTC-QLQ-C30 questionnaire</measure>
    <time_frame>once weekly during the neoadjuvant chemotherapy (5 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR(objective response rate) includes CR(complete rate) and PR(partial rate)</measure>
    <time_frame>Surgery scheduled 6-8 weeks after the end of chemoradiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of the concurrent chemotherapy cycles that patients can receive during radiotherapy</measure>
    <time_frame>once weekly during neoadjuvant chemoradiation(5 weeks,each cycle is one week)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>CRT with Dendrobium Huoshanense</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendrobium Huoshanense Granules: 3g tid per day for 5weeks
Concurrent Chemoradiotherapy:
Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
Chemotherapy in Interval Between CRT and Surgery:
Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
Surgery:
Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRT with Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 3g tid per day for 5weeks
Concurrent Chemoradiotherapy:
Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
Chemotherapy in Interval Between CRT and Surgery:
Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1
Surgery:
Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dendrobium Huoshanense Granules</intervention_name>
    <description>3g tid per day for 5weeks</description>
    <arm_group_label>CRT with Dendrobium Huoshanense</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic Radiation</intervention_name>
    <description>50Gy/25Fx</description>
    <arm_group_label>CRT with Dendrobium Huoshanense</arm_group_label>
    <arm_group_label>CRT with Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>625mg/m2 bid Monday-Friday per week</description>
    <arm_group_label>CRT with Dendrobium Huoshanense</arm_group_label>
    <arm_group_label>CRT with Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)</description>
    <arm_group_label>CRT with Dendrobium Huoshanense</arm_group_label>
    <arm_group_label>CRT with Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3g tid per day for 5weeks</description>
    <arm_group_label>CRT with Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathological confirmed rectum adenocarcinoma

          -  clinical stage T3-4 and/or N+

          -  the distance from anal verge less than 10 cm

          -  without distance metastases

          -  performance status score: 0~1

          -  UGT1A1*28 6/6 or 6/7

          -  without previous anti-cancer therapy

          -  able to follow the protocol during the study period

          -  sign the inform consent

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Those with other history of malignant disease in the past 5 years, except for cured
             skin cancer and cervical carcinoma in situ

          -  If there is an uncontrolled history of epilepsy, central nervous system disease or
             mental disorder, the investigator may determine that the clinical severity may hinder
             the signing of informed consent or affect the patient's oral medication compliance.

          -  Clinically severe (ie, active) heart disease, such as symptomatic coronary heart
             disease, New York Heart Association (NYHA) class II or more severe congestive heart
             failure or severe arrhythmia requiring medication intervention (see appendix 12), or a
             history of myocardial infarction in the last 12 months

          -  Organ transplantation requires immunosuppressive therapy

          -  Severe uncontrolled recurrent infections, or other serious uncontrolled concomitant
             diseases

          -  Subject blood routine and biochemical indicators do not meet the following criteria:
             hemoglobin ≥ 90g / L; absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; Alanine
             transaminase (ALT), aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of
             normal; alkaline phosphatase (ALP) ≤2.5 times the normal upper limit; serum total
             bilirubin &lt;1.5 times the normal upper limit; serum creatinine &lt;1 times the normal
             upper limit; serum albumin ≥ 30g / L

          -  Anyone who is allergic to any research medication

          -  DPD deficiency

          -  UGT1A1*28 7/7
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Zhu, MD</last_name>
    <phone>+86-2164175590</phone>
    <phone_ext>81607</phone_ext>
    <email>leo.zhu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhen Zhang, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhu Ji, MD</last_name>
      <email>leo.zhu@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhen Zhang, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 16, 2020</last_update_submitted>
  <last_update_submitted_qc>May 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhu Ji</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant Chemoradiotherapy</keyword>
  <keyword>Dendrobium Huoshanense</keyword>
  <keyword>irinotecan</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

